JP2008537748A5 - - Google Patents

Download PDF

Info

Publication number
JP2008537748A5
JP2008537748A5 JP2008505496A JP2008505496A JP2008537748A5 JP 2008537748 A5 JP2008537748 A5 JP 2008537748A5 JP 2008505496 A JP2008505496 A JP 2008505496A JP 2008505496 A JP2008505496 A JP 2008505496A JP 2008537748 A5 JP2008537748 A5 JP 2008537748A5
Authority
JP
Japan
Prior art keywords
compound
kinase
symbol placement
flt
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008505496A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008537748A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/012709 external-priority patent/WO2006108059A1/en
Publication of JP2008537748A publication Critical patent/JP2008537748A/ja
Publication of JP2008537748A5 publication Critical patent/JP2008537748A5/ja
Pending legal-status Critical Current

Links

JP2008505496A 2005-04-06 2006-04-06 ｃ−Ｍｅｔモジュレーター及び使用方法 Pending JP2008537748A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66920705P 2005-04-06 2005-04-06
PCT/US2006/012709 WO2006108059A1 (en) 2005-04-06 2006-04-06 C-met modulators and methods of use

Publications (2)

Publication Number Publication Date
JP2008537748A JP2008537748A (ja) 2008-09-25
JP2008537748A5 true JP2008537748A5 (https=) 2009-05-28

Family

ID=37073806

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008505496A Pending JP2008537748A (ja) 2005-04-06 2006-04-06 ｃ−Ｍｅｔモジュレーター及び使用方法

Country Status (6)

Country Link
US (1) US20080161305A1 (https=)
EP (1) EP1874759A4 (https=)
JP (1) JP2008537748A (https=)
AU (1) AU2006231646A1 (https=)
CA (1) CA2603748A1 (https=)
WO (1) WO2006108059A1 (https=)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2210607B1 (en) * 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
JP2009526761A (ja) 2006-01-30 2009-07-23 アレイ バイオファーマ、インコーポレイテッド ヘテロ二環式チオフェン化合物および使用の方法
PL2018380T3 (pl) 2006-05-19 2012-05-31 Abbvie Bahamas Ltd Skondensowane azabicykliczne pochodne alkanowe podstawione bicykloheterocyklem o aktywności wobec OUN
JP2009539878A (ja) * 2006-06-08 2009-11-19 アレイ バイオファーマ、インコーポレイテッド キノリン化合物および使用方法
MX2009008531A (es) 2007-02-16 2009-08-26 Amgen Inc Cetonas de heterociclilo que contienen nitrogeno y su uso como inhibidores de c-met.
JP2010519267A (ja) * 2007-02-22 2010-06-03 シンジェンタ パーティシペーションズ アクチェンゲゼルシャフト 新規殺微生物剤
US8148532B2 (en) 2007-03-14 2012-04-03 Guoqing Paul Chen Spiro substituted compounds as angiogenesis inhibitors
PE20090595A1 (es) 2007-08-15 2009-06-06 Glaxo Group Ltd Derivados de quinoliniloxipiperidina y pirrolidina como antagonistas del receptor h1
FR2922550B1 (fr) 2007-10-19 2009-11-27 Sanofi Aventis Nouveaux derives de 6-aryl/heteroalkyloxy benzothiazole et benzimidazole, application comme medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de cmet
NZ588355A (en) 2008-03-05 2012-03-30 Methylgene Inc Inhibitors of protein tyrosine kinase activity
JP4667537B2 (ja) * 2008-04-10 2011-04-13 大鵬薬品工業株式会社 アシルチオウレア化合物又はその塩、及びその用途
US8124764B2 (en) 2008-07-14 2012-02-28 Gilead Sciences, Inc. Fused heterocyclyc inhibitor compounds
CA2729909A1 (en) 2008-07-14 2010-01-21 Gilead Sciences, Inc. Imidazolyl pyrimidine inhibitor compounds
WO2010009166A1 (en) 2008-07-14 2010-01-21 Gilead Colorado, Inc. Oxindolyl inhibitor compounds
CN102123987A (zh) 2008-07-28 2011-07-13 吉里德科学公司 亚环烷基和亚杂环烷基组蛋白脱乙酰酶抑制剂化合物
ES2599458T3 (es) * 2008-10-14 2017-02-01 Sunshine Lake Pharma Co., Ltd. Compuestos y métodos de uso
JP5486606B2 (ja) * 2008-11-13 2014-05-07 エクセリクシス， インク． キノリン誘導体の調製方法
US20130030172A1 (en) * 2008-12-04 2013-01-31 Exelixis, Inc. Methods of Preparing Quinoline Derivatives
NZ779754A (en) 2009-01-16 2023-04-28 Exelixis Inc Malate salt of n-(4-{ [6,7-bis(methyloxy)quinolin-4-yl] oxy} phenyl)-n’-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
EP2408300B1 (en) * 2009-03-21 2016-05-11 Sunshine Lake Pharma Co., Ltd. Amino ester derivatives, salts thereof and methods of use
KR101106050B1 (ko) 2009-03-25 2012-01-18 한국과학기술연구원 아미노퀴놀린 화합물, 이의 제조 방법 및 이를 함유하는 의약 조성물
FR2945533B1 (fr) 2009-05-12 2011-05-27 Sanofi Aventis Derives de cyclopenta°c!pyrrolyl-alkylcarbamates d'heterocycles a 5 chainons, leur preparation et leur application en therapeutique
FR2945534B1 (fr) 2009-05-12 2012-11-16 Sanofi Aventis DERIVES DE CYCLOPENTAL[c]PYRROLE-2-CARBOXYLATES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
US8283357B2 (en) 2009-06-08 2012-10-09 Gilead Sciences, Inc. Cycloalkylcarbamate benzamide aniline HDAC inhibitor compounds
KR20120031170A (ko) 2009-06-08 2012-03-30 길리애드 사이언시즈, 인코포레이티드 알카노일아미노 벤즈아미드 아닐린 ｈｄａｃ 저해제 화합물
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
CN102030705B (zh) * 2009-09-30 2012-12-19 上海睿智化学研究有限公司 7-苄氧基-6-甲氧基-4-羟基喹啉的合成方法
DE102009056886A1 (de) 2009-12-03 2011-06-09 Bayer Schering Pharma Aktiengesellschaft cMet-Inhibitoren zur Behandlung der Endometriose
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
US9133123B2 (en) 2010-04-23 2015-09-15 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
NZ604306A (en) 2010-05-17 2015-02-27 Incozen Therapeutics Pvt Ltd Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases
EA030435B1 (ru) 2010-07-16 2018-08-31 Экселиксис, Инк. ТАБЛЕТКА, СОДЕРЖАЩАЯ МОДУЛЯТОР c-MET В ФОРМЕ КРИСТАЛЛИЧЕСКОЙ L-МАЛАТНОЙ СОЛИ (ВАРИАНТЫ), СПОСОБ ЕЕ ПРОИЗВОДСТВА И СПОСОБ ЛЕЧЕНИЯ ОНКОЛОГИЧЕСКОГО ЗАБОЛЕВАНИЯ С ЕЕ ИСПОЛЬЗОВАНИЕМ
US8664244B2 (en) 2010-09-12 2014-03-04 Advenchen Pharmaceuticals, LLC Compounds as c-Met kinase inhibitors
MX352926B (es) 2010-09-27 2017-12-14 Exelixis Inc Inhibidores dobles de met y factor de crecimiento endotelial vascular (vegf) para el tratamiento de cancer de prostata resistente a la castracion y metastasis osteoblasticas en los huesos.
US20140057908A1 (en) * 2010-09-27 2014-02-27 Exelixis, Inc. Method of Treating Cancer
BR112013020362A2 (pt) 2011-02-10 2018-05-29 Exelixis Inc processos para a preparação de compostos de quinolina, compostos e combinações farmacêuticas que os contem
US9604963B2 (en) 2011-03-04 2017-03-28 Glaxosmithkline Intellectual Property Development Limited Amino-quinolines as kinase inhibitors
US20120252840A1 (en) 2011-04-04 2012-10-04 Exelixis, Inc. Method of Treating Cancer
US8759380B2 (en) 2011-04-22 2014-06-24 Cytokinetics, Inc. Certain heterocycles, compositions thereof, and methods for their use
MX2013012695A (es) 2011-05-02 2014-03-27 Exelixis Inc Metodo para el tratamiento del cancer y el dolor por cancer de hueso.
TWI547494B (zh) 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
WO2013032797A2 (en) * 2011-08-26 2013-03-07 New Hope R & D Bioscience, Inc. Oxetane 3,3-dicarboxamide compounds and methods of making and using same
EP2758057B1 (en) 2011-09-22 2017-05-31 Exelixis, Inc. Method for treating osteoporosis
CN104395284A (zh) 2011-10-20 2015-03-04 埃克塞里艾克西斯公司 制备喹啉衍生物的方法
TWI594986B (zh) * 2011-12-28 2017-08-11 Taiho Pharmaceutical Co Ltd Antineoplastic agent effect enhancer
CN102617463A (zh) * 2012-02-28 2012-08-01 苏州卡耐博生物技术有限公司 喹啉衍生物和喹唑啉衍生物及它们的制备方法
CN107082779A (zh) 2012-03-30 2017-08-22 理森制药股份公司 作为c‑met 蛋白激酶调节剂的新化合物
WO2013166296A1 (en) 2012-05-02 2013-11-07 Exelixis, Inc. A dual met - vegf modulator for treating osteolytic bone metastases
AR092529A1 (es) 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
TW201425307A (zh) 2012-09-13 2014-07-01 Glaxosmithkline Llc 作為激酶抑制劑之胺基－喹啉類
CN103664776B (zh) * 2012-09-26 2016-05-04 正大天晴药业集团股份有限公司 一种酪氨酸激酶抑制剂及其中间体的制备方法
CN103965104B (zh) * 2013-01-29 2017-09-29 正大天晴药业集团股份有限公司 一种酪氨酸激酶抑制剂及其中间体的制备方法
CA2902132C (en) 2013-02-21 2020-09-22 Glaxosmithkline Intellectual Property Development Limited Quinazolines as kinase inhibitors
CA2907334C (en) 2013-03-15 2021-12-07 Exelixis, Inc. Metabolites of n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
US11564915B2 (en) 2013-04-04 2023-01-31 Exelixis, Inc. Cabozantinib dosage form and use in the treatment of cancer
BR112016018450A2 (pt) 2014-02-14 2018-09-18 Exelixis Inc formas sólidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida, processos de preparo e métodos de uso
EP3119476A1 (en) 2014-03-17 2017-01-25 Exelixis, Inc. Dosing of cabozantinib formulations
EP3174854B1 (en) 2014-07-31 2022-08-24 Exelixis, Inc. Method of preparing fluorine-18 labeled cabozantinib and its analogs
MX382904B (es) 2014-08-05 2025-03-13 Exelixis Inc Combinaciones de fármacos para tratar mieloma múltiple.
CN106279147A (zh) * 2015-05-21 2017-01-04 中国科学院上海药物研究所 一种吡啶并氮杂环化合物及其制备方法和用途
JP6740354B2 (ja) 2015-10-05 2020-08-12 ザ トラスティーズ オブ コロンビア ユニバーシティー イン ザ シティー オブ ニューヨーク オートファジーの流れ及びホスホリパーゼｄ及びタウを含むタンパク質凝集体のクリアランスの活性化剤ならびにタンパク質症の治療方法
EP3442531A1 (en) 2016-04-15 2019-02-20 Exelixis, Inc. Method of treating renal cell carcinoma using n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluoropheny)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate
WO2018026877A1 (en) 2016-08-05 2018-02-08 Calitor Sciences, Llc Process for preparing substituted quinolin-4-ol compounds
CN108069919A (zh) * 2016-11-08 2018-05-25 上海医药工业研究院 咔哒唑胺关键中间体的制备方法
WO2018151177A1 (ja) 2017-02-15 2018-08-23 大鵬薬品工業株式会社 医薬組成物
JP7074760B2 (ja) 2017-09-08 2022-05-24 大鵬薬品工業株式会社 抗腫瘍剤及び抗腫瘍効果増強剤
CN111303024B (zh) * 2018-12-12 2023-03-28 安徽中科拓苒药物科学研究有限公司 一种喹啉结构的pan-KIT激酶抑制剂及其用途
CN110423218A (zh) * 2019-08-09 2019-11-08 新乡双鹭药业有限公司 一种苹果酸卡博替尼合成中杂质的制备方法
CN116997544A (zh) * 2021-03-24 2023-11-03 法国施维雅药厂 用于合成5-{5-氯-2-[(3s)-3-[(吗啉-4-基)甲基]-3,4-二氢异喹啉-2(1h)-羰基]苯基}-1,2-二甲基-1h-吡咯-3-甲酸衍生物的新方法及其在生产药物化合物中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH585221A5 (https=) * 1972-07-28 1977-02-28 Synthelabo
US5278760A (en) * 1990-04-20 1994-01-11 Hitachi America, Ltd. Method and system for detecting the misfire of an internal combustion engine utilizing engine torque nonuniformity
US5041980A (en) * 1990-06-04 1991-08-20 Caterpillar Inc. Method and apparatus for producing fault signals responsive to malfunctions in individual engine cylinders
US5222392A (en) * 1990-09-21 1993-06-29 Nippondenso Co., Ltd. Control system with misfire detection function for internal combustion engine
JP3357091B2 (ja) * 1992-07-21 2002-12-16 富士重工業株式会社 エンジンの失火検出方法
JP2856014B2 (ja) * 1993-02-05 1999-02-10 三菱自動車工業株式会社 クランク軸回転変動による失火検出方法
US5574217A (en) * 1995-06-06 1996-11-12 Chrysler Corporation Engine misfire detection with compensation for normal acceleration of crankshaft
US5542291A (en) * 1995-08-04 1996-08-06 Ford Motor Company Misfire detection in an internal combustion engine using modified median averaging
US5728941A (en) * 1995-10-09 1998-03-17 Denso Corporation Misfire detecting apparatus using difference in engine rotation speed variance
JPH09137747A (ja) * 1995-11-15 1997-05-27 Unisia Jecs Corp 内燃機関の失火診断装置
JP3449170B2 (ja) * 1996-08-09 2003-09-22 トヨタ自動車株式会社 内燃機関の失火検出装置
WO1998013350A1 (en) * 1996-09-25 1998-04-02 Zeneca Limited Qinoline derivatives inhibiting the effect of growth factors such as vegf
JP3477016B2 (ja) * 1997-02-19 2003-12-10 株式会社日立製作所 内燃機関の燃焼状態検出装置
ATE232205T1 (de) * 1998-10-01 2003-02-15 Astrazeneca Ab Chinolin- und chinazolin derivate und ihre verwendung als inhibitoren von krankheiten, bei denen cytokine beteiligt wird
GB9904103D0 (en) * 1999-02-24 1999-04-14 Zeneca Ltd Quinoline derivatives
DK1382604T3 (da) * 2001-04-27 2006-04-18 Kirin Brewery Quinolinderivater med en azolylgruppe og quinazolinderivater
AU2002313249B2 (en) * 2001-06-22 2008-08-21 Kirin Pharma Kabushiki Kaisha Quinoline derivative and quinazoline derivate inhibiting self-phosphorylation of hepatocytus proliferator receptor, and medicinal composition containing the same

Similar Documents

Publication Publication Date Title
JP2008537748A5 (https=)
Smith et al. Autophagy, cancer stem cells and drug resistance
Gay et al. Pharmacokinetic drug‐drug interactions of tyrosine kinase inhibitors: A focus on cytochrome P450, transporters, and acid suppression therapy
EP2776037B1 (en) Method of treating a proliferative disease
Kolb et al. Initial testing of dasatinib by the pediatric preclinical testing program
JP2009514881A5 (https=)
WO2013007708A1 (en) Medicament for treatment of liver cancer
RU2006108791A (ru) N-замещенные пиразолиламидилбензимидазолилы в качестве с-kit ингибиторов
GEP20125469B (en) Inhibitors of akt activity
EA201001412A1 (ru) Ингибиторы киназы pim и способы их применения
JP2009514880A5 (https=)
UA109878C2 (uk) Похідні ізохінолінону, фармацевтична композиція на їх основі (варіанти) та спосіб лікування захворювань (варіанти)
JP2006523238A5 (https=)
NI200800060A (es) Bencimidazoles sustituidos como inhibidores de cinasa.
WO2011081493A3 (en) Pharmaceutical composition comprising metformin and rosuvastatin
MA32458B1 (fr) Combinaison d'un antagoniste de c-met et d'un compose aminoheteroaryle pour le traitement d'un cancer
AR069244A1 (es) Metodos para administrar n-( 5- ter- butil- isoxixasol-3-il) -n'- (4(7-(2- morfolin-4-il- etoxi) imidazo (2,1-b) (1,3) benzotiazol -2-il) fenil) urea para tratar una enfermedad proliferante y composicion farmaceutica
BR112012008325A2 (pt) N-4 ( - ( ( 3- ( 2 - amino-4 pirimidinil) -2 -piridinil) oxi) fenil) -4- (4-metil-2-tienil) -1- ftalazinamina para uso no tratamento de câncer resistente a agente antimitótico
RU2012108423A (ru) Ацилгуанидиновые производные с азотсодержащим циклом
Liu et al. BRAF mutation‐selective inhibition of thyroid cancer cells by the novel MEK inhibitor RDEA119 and genetic‐potentiated synergism with the mTOR inhibitor temsirolimus
Anai et al. Antitumor effect of fibrin glue containing temozolomide against malignant glioma
JP2013520499A5 (https=)
RU2007120690A (ru) Комбинации антагонистов никотинового ацетилхолинового альфа-7-рецептора
BR0211855A (pt) Medicamento e método para tratamento e melhoria da qualidade restauradora do sono
Azanza et al. Comparative pharmacology of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia